Drug intelligence / Profile preview

IMG-013

Development stage: Unknown
Lead developer: Inmagene Biopharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

IMG-013 is a monoclonal antibody targeting the alpha chain of the interleukin-7 receptor (IL-7Rα; CD127). It acts as an inhibitor of IL-7Rα signaling. The drug is being developed for potential use in autoimmune and inflammatory diseases. Initially developed by Maijin Biomedical Technology (Shanghai), it has also been associated with Inmagene Biopharmaceuticals and Ornovi, Inc. As of early 2025, its highest development phase is preclinical[1][2][3].

Targets

IL7R (Interleukin-7 Receptor)

Beyond the preview

Go deeper on IMG-013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMG-013.

Explore the full profile